Page Executive
Chief Medical Officer - Injectable Neurotoxin Aesthetics
Page Executive, Raleigh, North Carolina, United States, 27601
Chief Medical Officer – Injectable Neurotoxin Aesthetics
Join us as we bring a next‑generation injectable neurotoxin platform to market. This executive role will lead clinical strategy through FDA approval and future commercialization.
About Our Client Partnering with a venture‑capital backed biotech developing a next‑generation injectable neurotoxin platform for aesthetic indications, we are seeking a Chief Medical Officer to lead clinical strategy through FDA approval.
Key Responsibilities
Lead Phase II/III global clinical trial design and execution.
Serve as the primary medical interface with the FDA (End‑of‑Phase, pre‑BLA, BLA support).
Define clinical endpoints, safety strategy, and benefit‑risk positioning aligned with regulatory and commercial goals.
Build and leverage strong KOL and investigator networks in aesthetics, dermatology, and plastic surgery.
Oversee medical affairs strategy, scientific communications, and advisory boards.
Partner with CRO and Regulatory, Clinical Ops, Commercial, and BD experts.
Present clinical strategy and data to the Board and investors.
MPI does not discriminate on the basis of race, religion, sex, sexual orientation, gender identity or expression, age, disability, marital status, or based on an individual’s status in any protected class. MPI encourages applications from minorities, women, the disabled, and all other qualified applicants.
The Successful Applicant
MD (or equivalent) required.
Demonstrated hands‑on leadership of late‑stage clinical programs through FDA approval.
Deep experience in injectable aesthetics/neurotoxins or closely related therapeutic areas.
Prior senior medical leadership experience (CMO, SVP, VP Clinical/Medical).
Strong FDA engagement experience and credibility with external stakeholders.
Established KOL relationships within the U.S. and global aesthetics community.
Well‑suited for senior medical leaders from global leading aesthetic‑focused organizations ready to take full ownership of an asset and shape its trajectory from late‑stage development to market.
What's on Offer
Executive ownership of a high‑value, differentiated neurotoxin asset.
Direct influence on clinical, regulatory, and medical strategy.
Meaningful equity upside in a VC‑backed growth platform.
Opportunity to transition from large pharma to a high‑impact, decision‑driving CMO role.
If you are ready to take on this exciting Chief Medical Officer role, apply now to join a leading organization in the financial services industry.
Quote job ref: JN‑122025‑6896750
Seniority level Executive
Employment type Full‑time
Job function Health Care Provider
Industries Pharmaceutical Manufacturing
#J-18808-Ljbffr
About Our Client Partnering with a venture‑capital backed biotech developing a next‑generation injectable neurotoxin platform for aesthetic indications, we are seeking a Chief Medical Officer to lead clinical strategy through FDA approval.
Key Responsibilities
Lead Phase II/III global clinical trial design and execution.
Serve as the primary medical interface with the FDA (End‑of‑Phase, pre‑BLA, BLA support).
Define clinical endpoints, safety strategy, and benefit‑risk positioning aligned with regulatory and commercial goals.
Build and leverage strong KOL and investigator networks in aesthetics, dermatology, and plastic surgery.
Oversee medical affairs strategy, scientific communications, and advisory boards.
Partner with CRO and Regulatory, Clinical Ops, Commercial, and BD experts.
Present clinical strategy and data to the Board and investors.
MPI does not discriminate on the basis of race, religion, sex, sexual orientation, gender identity or expression, age, disability, marital status, or based on an individual’s status in any protected class. MPI encourages applications from minorities, women, the disabled, and all other qualified applicants.
The Successful Applicant
MD (or equivalent) required.
Demonstrated hands‑on leadership of late‑stage clinical programs through FDA approval.
Deep experience in injectable aesthetics/neurotoxins or closely related therapeutic areas.
Prior senior medical leadership experience (CMO, SVP, VP Clinical/Medical).
Strong FDA engagement experience and credibility with external stakeholders.
Established KOL relationships within the U.S. and global aesthetics community.
Well‑suited for senior medical leaders from global leading aesthetic‑focused organizations ready to take full ownership of an asset and shape its trajectory from late‑stage development to market.
What's on Offer
Executive ownership of a high‑value, differentiated neurotoxin asset.
Direct influence on clinical, regulatory, and medical strategy.
Meaningful equity upside in a VC‑backed growth platform.
Opportunity to transition from large pharma to a high‑impact, decision‑driving CMO role.
If you are ready to take on this exciting Chief Medical Officer role, apply now to join a leading organization in the financial services industry.
Quote job ref: JN‑122025‑6896750
Seniority level Executive
Employment type Full‑time
Job function Health Care Provider
Industries Pharmaceutical Manufacturing
#J-18808-Ljbffr